Quantcast

Latest Panitumumab Stories

2009-09-24 02:37:00

THOUSAND OAKS, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '203' trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone, (hazard...

2009-09-22 02:01:00

THOUSAND OAKS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC. These results were presented at the 2009 ECCO 15 - ESMO 34...

2009-09-16 08:00:00

THOUSAND OAKS, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany. Researchers will present data from two Phase 3 head-to-head studies evaluating denosumab versus Zometa(R) (zoledronic acid) for the treatment of bone metastases in patients with advanced breast cancer (the '136'...

2009-08-21 10:06:07

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients. Now the discovery of genetic biomarkers relevant to CRC means that targeted personalized medication is increasingly common.CRC affects approximately 150,000 patients and leads to over 52,000 deaths every year in the US alone. In the early stages, CRC can often...

2009-08-17 16:07:00

THOUSAND OAKS, Calif., Aug. 17 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced positive top-line results from a Phase 3 trial evaluating Vectibix((R) )(panitumumab) in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients with metastatic colorectal cancer (mCRC). The co-primary endpoints, tested independently, were progression-free and overall survival. Vectibix significantly improved progression-free survival in...

2009-08-06 15:03:00

THOUSAND OAKS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that Vectibix((R)) (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with FOLFOX alone in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC). "We believe that these data document an important advance for patients with metastatic colorectal cancer,"...

2009-08-06 06:00:00

BETHESDA, Md., Aug. 6 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the second quarter and six months ended June 30, 2009. In the second quarter of 2009, Micromet achieved a number of significant milestones illustrating its continued progress in the clinic and in corporate development. The milestones...

2009-08-04 16:09:00

SALT LAKE CITY, Aug. 4 /PRNewswire/ -- ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, supports the U.S. Food and Drug Administration's (FDA) decision to put KRAS on the label of two targeted drugs, Vectibix (panitumumab) and Erbitux (cetuximab). On July 17, 2009, the FDA noted that, "retrospective analyses of metastatic colorectal cancer trials have not shown a treatment benefit for...

2009-07-17 18:10:00

THOUSAND OAKS, Calif., July 17 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for the epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix((R)) (panitumumab). This decision follows the FDA's December 2008 Oncologics Drugs Advisory Committee (ODAC) meeting where the clinical utility of the KRAS gene as a predictive biomarker in patients with...

2009-06-01 07:09:00

- Results from a randomized Phase IIb trial reported at 2009 ASCO Annual Meeting - MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with inoperable,...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'